health
Dyskinesia Reduction
Dyskinesia Reduction refers specifically to a decrease in dyskinesia, the outcome being measured. It describes less of this symptom, not necessarily improvement in every other symptom, health concern, or underlying condition.
Dyskinesia Reduction is a health-related effect focused on a decrease in dyskinesia.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not tested in people
CyclingpracticeNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
A proposed effect is reduced motor fluctuations and dyskinesia severity in people with Parkinson's disease, particularly with high-cadence or tandem training.
Open the Cycling page
The expert view shows every study, dose protocol and source.
What may help
Linked to improving it1 listedStart here
The best we have, but the evidence is still weak
- →PracticesCyclingCertaintyLowSourceTheoretical1 other source
A proposed effect is reduced motor fluctuations and dyskinesia severity in people with Parkinson's disease, particularly with high-cadence or tandem training.
Open CyclingStudy result
Cycling may reduce motor fluctuations and dyskinesia severity in Parkinson’s disease patients, particularly with high-cadence or tandem training.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Dyskinesia Reduction refers specifically to a decrease in dyskinesia, the outcome being measured. It describes less of this symptom, not necessarily improvement in every other symptom, health concern, or underlying condition. Research on this outcome has included interventions such as CBD (Cannabidiol), Ginkgo Biloba, and L-Theanine.
How interventions help
The interventions associated with dyskinesia reduction are not interchangeable. They differ in how quickly a change was observed, whether use was continuous, and how the outcome was measured. Ginkgo Biloba was evaluated over 12 weeks at 240 mg/day, with the reported difference appearing at week 12. By contrast, the CBD finding associated with improvement became nominally significant on Day 6, when participants were receiving 7.5 mg/kg/day; daily use was not specified as required.
Other approaches were assessed over longer, defined periods. L-Theanine was studied with Vitamin B6 for 2 months, while Alpha-Lipoic Acid (ALA) was evaluated at 300 mg/day for 8 weeks. The reported changes therefore describe outcomes after sustained use rather than an immediate response. Vitamin B6 reports described subjective improvement without complete resolution, and community reports concerning Magnesium and Vitamin B2 (Riboflavin) do not establish a measured clinical change.
CBD also appears in a separate acute context with a different direction of association. After an acute single dose of 1000 mg, the THC+CBD condition was reported as approximately 2 points higher than THC alone. This means CBD-related findings should be read in context rather than combined into one general expectation of improvement.
Because the health status of participants was not specified, these findings do not identify which people are most likely to respond. The page also brings together measured outcomes, subjective reports, and community observations, so the practical certainty and relevance vary across interventions.
Choosing guidance
For readers prioritizing human trial evidence, Ginkgo Biloba and Alpha-Lipoic Acid (ALA) stand apart from options supported mainly by reviews or anecdotal reports. Ginkgo Biloba was evaluated over a planned course, while Alpha-Lipoic Acid (ALA) was examined in a smaller pilot study over a shorter period. These distinctions matter when considering whether an option has been tested beyond immediate effects and whether its findings apply to people rather than only reports or interpretation of earlier literature.
CBD (Cannabidiol) warrants especially careful interpretation because it appears in both an improvement-related entry and a causes-related entry. Its reported improvement was not immediate, emerging after several days, whereas the other finding involved an acute single exposure. This makes timing and context important rather than treating CBD as a uniformly suitable choice.
L-Theanine was studied alongside Vitamin B6 (Pyridoxine), so its finding does not isolate L-Theanine alone. Vitamin B6 (Pyridoxine) is described through subjective reports and was discontinued, while Vitamin B9 (Folate), Magnesium, and Vitamin B2 (Riboflavin) have less direct support in the listed material. These options may be of interest when reviewing preliminary or experience-based possibilities, but they are less informative for someone seeking a clearly tested, time-defined approach.